Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLS | O94925 | 20/20 | 0.81 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17654184 | 0.90 | GLS (1.00) | GLS | |
| SCHEMBL30369423 | 0.90 | GLS (1.00) | GLS | |
| SCHEMBL17654105 | 0.88 | GLS (0.81) | GLS | |
| SCHEMBL17654142 | 0.83 | GLS (0.82) | GLS | |
| SCHEMBL17654172 | 0.81 | GLS (0.72) | GLS | |
| SCHEMBL17654037 | 0.78 | GLS (1.00) | GLS | |
| SCHEMBL30369411 | 0.78 | GLS (1.00) | GLS | |
| SCHEMBL17654103 | 0.78 | GLS (1.00) | GLS | |
| SCHEMBL17654186 | 0.77 | GLS (0.68) | GLS | |
| SCHEMBL30369618 | 0.77 | GLS (0.68) | GLS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11013724-B2 | Glutaminase inhibitors | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2021-05-25 | — | — | US | claimed |
| US-20190167648-A1 | GLUTAMINASE INHIBITORS | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2019-06-06 | — | — | US | claimed |
| US-10245254-B2 | Glutaminase inhibitors | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2019-04-02 | — | — | US | claimed |
| US-20170290815-A1 | GLUTAMINASE INHIBITORS | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2017-10-12 | — | — | US | claimed |
| WO-2016054388-A1 | GLUTAMINASE INHIBITORS | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2016-04-07 | — | — | WO | claimed |
| EP-3713569-B1 | THERAPEUTIC PARTICLE COMPRISING A YAP1/WWRT1 INHIBITING AGENT AND THE GLUTAMINASE INHIBITING AGENT 2-CYCLOPROPYL-N-[5-(4-{ [5-(2-PHENYLACETAMIDO)-1,3,4-THIADIAZOL-2-YL]AMINO}PIPERIDIN-1-YL)-1,3,4-THIADIAZOL-2-YL] ACETAMIDE AND USE THEREOF FOR TREATING A PULMONARY DISEASE | UNIV PITTSBURGH COMMONWEALTH SYS HIGHER EDUCATION (US) | 2024-03-13 | — | — | EP | disclosed |
| WO-2023081775-A1 | COMBINATION INHIBITORS FOR TREATING FIBROSIS | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2023-05-11 | — | — | WO | disclosed |
| US-11013724-B2 | Glutaminase inhibitors | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2021-05-25 | — | — | US | disclosed |
| US-20200276125-A1 | COMPOSITIONS AND METHODS FOR ADMINISTERING A YAP1/WWRT1 INHIBITING COMPOSITION AND A GLS1 INHIBITING COMPOSITION | UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2020-09-03 | — | — | US | disclosed |
| US-20190167648-A1 | GLUTAMINASE INHIBITORS | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2019-06-06 | — | — | US | disclosed |
| US-10245254-B2 | Glutaminase inhibitors | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2019-04-02 | — | — | US | disclosed |
| US-20170290815-A1 | GLUTAMINASE INHIBITORS | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2017-10-12 | — | — | US | disclosed |
| WO-2016054388-A1 | GLUTAMINASE INHIBITORS | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2016-04-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170290815-A1 | GLUTAMINASE INHIBITORS | GLUL, ASNS, GLS | GLS 3/4885 |
| US-10245254-B2 | Glutaminase inhibitors | GLUL, ASNS, GLS | GLS 3/4885 |
| US-20190167648-A1 | GLUTAMINASE INHIBITORS | GLUL, ASNS, GLS | GLS 3/4885 |
| US-20200276125-A1 | COMPOSITIONS AND METHODS FOR ADMINISTERING A YAP1/WWRT1 INHIBITING COMPOSITION AND A GLS1 INHIBITING COMPOSITION | GLS2, GLS, YAP1 | GLS 2/4885 |
| US-11013724-B2 | Glutaminase inhibitors | GLUL, ASNS, GLS | GLS 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.